RxDoctor Payments Data

Emmanuel Luna, MD

Family Medicine · Glendale, CANPI 1316968571

Payments from drug & device makers

$1,537in general payments, 2019–2025

Across 46 payments — averaging $33.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$536
  • Exact Sciences$207
  • Bayer$146
  • Pfizer$134
  • Boehringer Ingelheim$133
  • Lilly USA, LLC$94
  • plus $286 from 5 others

What the payments were for

  • Food & beverage$1,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,537 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$23,001
Medicare patients
59
Services billed
175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide35$55,817
OzempicSemaglutide30$28,450
JardianceEmpagliflozin11$14,415
EliquisApixaban16$11,059
PremarinEstrogens, Conjugated14$6,462
VascepaIcosapent Ethyl14$5,931
TradjentaLinagliptin11$5,474
Atorvastatin Calcium312$2,262
Fenofibric AcidFenofibric Acid (Choline)30$2,244
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,099
Losartan Potassium261$2,060
Metformin Hcl193$1,384
Valsartan40$1,378
Sucralfate38$1,173
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril29$1,004

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$536$84,26865 claims
Boehringer IngelheimJardiance, Tradjenta$133$19,88922 claims
PfizerEliquis, Premarin$134$17,52130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →